<DOC>
	<DOCNO>NCT01286935</DOCNO>
	<brief_summary>The purpose study determine long-term efficacy safety two dos safinamide ( 50 100 mg/day , p.o ) , compare placebo , add-on therapy patient idiopathic Parkinson 's disease motor fluctuation , currently receive stable dose levodopa .</brief_summary>
	<brief_title>18-month Study Long-term Efficacy &amp; Safety Safinamide add-on Therapy Patients With Mid-late Stage PD</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>The patient complete 24 week treatment Study 016 , , patient discontinue prematurely , he/she return schedule efficacy evaluation Weeks 12 24 , part Retrieved Dropout ( RDO ) population . The patient compliant take study medication Study 016 . The patient willing participate study sign approve Informed Consent form . The patient experience clinically significant adverse event would put patient risk participate study . The patient show clinically significant deterioration participation Study 016 , reach Hoehn Yahr Stage V. The patient discontinue Study 016 prematurely reason , return schedule efficacy evaluation Weeks 12 24 .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Parkinson 's Disease</keyword>
	<keyword>PD</keyword>
	<keyword>Levodopa</keyword>
	<keyword>Patients idiopathic Parkinson 's Disease motor fluctuation ,</keyword>
</DOC>